Passage Bio has launched to develop treatments for diseases affecting the central nervous system, after raising almost $116m in a series A round backed by Lilly Asia Ventures.

CK Hutchinson's Longliv fund has made its first investment, leading the medical diagnostic system producer's $27.8m series C round.

Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.

UBC and CDRD spinout Sitka Biopharma has now lured $5.5m in total and is readying its bladder cancer treatment for initial clinical trials.

Complion collected funding from investors including the multi-university-backed Ohio Innovation Fund for its regulatory compliance software platform catered to sites conducting clinical research.

Regenerative craniofacial implant manufacturer OssDsign has amassed $19.7m altogether as it prepares to take its products based on Karolinska and Uppsala university research into new markets.

The gains came against a backdrop of falling net profits and cash reserves that will test Karolinska Development as it looks ahead to convertible debt obligations.

Legend Capital led a $29.5m round for SciWind, which is developing treatments for metabolic and liver diseases, with backing from Kawin Technology.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Axovant Sciences has spun out its small molecule team into a startup called Arvelle, which will develop an anti-epileptic drug after raising more than $100m in external funding.